Ranibizumab 0.5 MG/0.05 ML Intraocular Solution [LUCENTIS]

DRUG3 trials

Sponsors

Bernardete Pessoa MD, Renmin Hospital of Wuhan University, Centro Hospitalar do Porto

Conditions

Diabetic Macular EdemaDiabetic RetinopathyMacular EdemaRetinal Vein Occlusion

Unknown Phase

Intravitreal Ranibizumab or Aflibercept After Bevacizumab in Diabetic Macular Edema

CompletedNCT04018833

Bernardete Pessoa MDDiabetic Macular Edema, Diabetic Retinopathy

Start: 2012-01-01End: 2016-06-30Updated: 2019-07-23

Ultra-wide-field Fluorescein Angiography in Patients With Macular Edema Secondary to Retinal Vein Occlusion

Renmin Hospital of Wuhan UniversityMacular Edema, Retinal Vein Occlusion

Start: 2023-10-09End: 2025-12-15Target: 60Updated: 2023-10-18

Effect of the Vitreous in Response to Intravitreal Injections of Ranibizumab for the Treatment of Diabetic Macular Edema

CompletedNCT04387604

Centro Hospitalar do PortoDiabetic Macular Edema

Start: 2017-08-01End: 2019-03-01Updated: 2020-05-14

Related Papers

Oct biomarkers for early prognosis in diabetic macular edema treatment with ranibizumab

European Journal of Ophthalmology2023-11-031 citations

Vitrectomized versus non-vitrectomized eyes in diabetic macular edema response to ranibizumab-retinal layers thickness as prognostic biomarkers.

2021-11-293 citations

Choroidal Blood Flow After Intravitreal Ranibizumab in Vitrectomized and Non-Vitrectomized Eyes with Diabetic Macular Edema

Clinical ophthalmology2021-10-014 citations

Intravitreal Ranibizumab or Aflibercept After Bevacizumab in Diabetic Macular Edema: Exploratory Retrospective Analysis

Clinical ophthalmology2021-01-016 citations